ZNF740 and acute myeloid leukemia: To validate the role of ZNF740 in therapeutic response to venetoclax in AML cells, we utilized competitive proliferative assay to assess the impact of ZNF740 knockout on cell fitness following treatment with venetoclax or DMSO in OCI-AML2 and MOLM-13 cell lines (Fig. 2A).